What the trial was testing
The ARIEL4 enrolled 349 patients with ovarian cancer. The study was sponsored by pharmaand GmbH and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Women on rucaparib went 7.4 months without cancer growth versus 5.7 months on chemotherapy.
The Lancet. Oncology · 2022 · NCT02855944
These findings — that time before cancer grew on rucaparib compared to chemotherapy — were published in the The Lancet. Oncology and represent the headline result of the study.
Researchers tracked outcomes across 349 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with ovarian cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rucaparib is FDA-approved for ovarian cancer with BRCA mutations. If you have relapsed ovarian cancer and carry a BRCA1 or BRCA2 mutation, talk to your oncologist about whether rucaparib is right for you. It may offer more time before cancer progresses compared to chemotherapy.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open ovarian cancer trials
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.